Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 8Melanoma 4Uveal Melanoma 3Sarcoma 3Leukemia, Myeloid, Acute 3Glioblastoma 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Mesothelioma, Malignant 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Skin Neoplasms 1Resectable Hepatocellular Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leiomyosarcoma 1Ichthyosis, X-Linked 1HER2 Negative Metastatic Breast Cancer 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Cancers 1Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 1Sirolimus 1Nivolumab 1Ipilimumab 1Docetaxel 1Albumin-Bound Paclitaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Cancers × ADI PEG20 × Clear all
NCT03254732 2022-04-27

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Polaris Group

Phase 1 Terminated
33 enrolled

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡